1. A use of a pharmaceutical formulation suitable for, adapted for, and/or packaged and presented for, topical adminstration, comprising montelukast, or a pharmaceutically acceptable salt of solvate thereof, in admixture with a pharmaceutically-acceptable topical adjuvant, diluent or carrier for the manufacture of a medicament for the healing or the recovery of a wound or a burn of the skin or of the mucosa, by direct topical application of said formulation to said wound or burn.
2. The use as claimed in claim 1, wherein the wound is selected from the group consisting of: an abrasion, a scratch, an incision, a laceration, a skin puncture, an avulsion, a bruise, a scar and a blister.
3. The use as claimed in Claim 1, wherein the wound is hemorrhoids.
4. The use as claimed in Claim 1, wherein the wound or burn is caused by heat, a chemical, sunburn, chilblains or frostbite.
5. The use as claimed in Claim 1, wherein the wound is a consequence of a disease or a disorder.
6. The use as claimed in Claim 5, wherein the wound is an ulcer of the skin or the mucosa.
7. The use as claimed in Claim 6, wherein the ulcer is a gastric ulcer.
8. The use as claimed in Claim 5 or Claim 6, wherein the disease or disorder is ulcerative colitis.
9. The use as claimed in Claim 5 or Claim 6, wherein the disease or disorder is esophagitis or gastritis.
10. The use as claimed in any one of the preceding claims wherein the wound or burn comprises damage to and/or below the epidermis or the dermis.
11. The use as claimed in Claim 9, wherein the damage comprises damage to muscles, bones, joints and/or internal organs.
12. The use as claimed in any one of the preceding claims, wherein the formulation further treats the or pain and/or itching associated with the wound or burn or healing processes associated therewith.

13. The use as claimed in any one of the preceding claims, wherein the formulation further prevents the exudation of body fluids and/or the risk of infection resulting from the wound or the burn, and/or further prevents physiological reactions that result from wound healing processes or burn healing processes.
14. The use as claimed in Claim 13, wherein the physiological reaction comprises scarring and/or melanin pigmentation.
15. The use as claimed in Claim 14, wherein the melanin pigmentation is associated with chloasma, freckles, melanosis, malar rash, another chromatosis, a skin cancer with melanoma, and/or a chromatosis that is caused by exposure to the sun.
16. The use as claimed in any one of Claims 1 to 6 or 10 to 15, wherein the topical adminstration is to the skin.
17. The use as claimed in any one of Claims 1 to 9, 12 or 13, wherein the topical adminstration is to a mucosal surface.
18. The use as claimed in any one of the preceding claims, wherein the formulation is in the form of a gel, a cream or an ointment.
19. The use as claimed in Claim 18, wherein the formulation further comprises a polyethylene glycol.
20. The use as claimed in Claim 19, wherein the polyethylene glycol is polyethylene glycol 400.
21. The use as claimed in Claim 14, wherein the physiological reaction comprises scarring.
22. The use as claimed in Claim 17 or Claim 21, wherein the topical administration is pulmonary administration to the mucosal surface.
23. The use as claimed in Claim 22, wherein the pulmonary administration is tracheally or bronchially.
24. The use as claimed in Claim 22 or Claim 23, wherein the pulmonary administration is to treat inhalation injury.

25. The use as claimed in any one of Claims 22 to 25, wherein the formulation is in the form of a liquid spray for inhalation.
26. The use as claimed in any one of the proceeding claims wherein the formulation further comprises at least one mussel adhesive protein or a derivative thereof.
27. The use as claimed in any one of Claims 1 to 25 wherein the formulation is part of a kit of parts further comprising a pharmaceutical formulation including at least one mussel adhesive protein or a derivative thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, wherein the two formulations are each provided in a form that is suitable for administration in conjunction with the other.
28. The use as claimed in Claim 27, wherein the two formulation are suitable for sequential, separate and/or simultaneous use in the treatment of the wound or the burn.
29. The use as claimed in any one of Claims 26 to 28, wherein the at least one mussel adhesive protein is selected from the group: mefp-1 mefp-2, mefp-3, mefp-4, mefp-5, mefp-6 and combinations thereof.
30. The use as claimed in Claim 29, wherein the at least one mussel adhesive protein comprises mefp-1.
31. The use as claimed in any one of Claims 26 to 28 comprising a derivative of a mussel adhesive protein, which is a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof.